Skip to content Skip to footer
VIEWPOINTS_Michael Irizarry_2023

Michael Irizarry shares insights from the P-III clinical study of LEQEMBI, for the treatment of Alzheimer’s disease

Shots:Michael Irizarry, Senior VP of Clinical Research and Deputy Chief Clinical Officer, Alzheimer’s Disease and Brain Health at Eisai in a stimulating conversation with PharmaShotsMichael shares insights from the P-III clinical study Clarity AD of LEQEMBI for the treatment of Alzheimer’s diseaseThe study highlights that LEQEMBI treatment met the primary endpoint and…

Read more